Key result
There is insufficient evidence to regard increased homocysteine levels as a causative factor in atherosclerotic disease or to support widespread folic acid therapy for cardiovascular risk reduction.
Why the study?
An increased plasma level of homocysteine has been proposed as an independent risk factor for atherosclerosis, but contradictory data exist regarding its role in disease progression.
Does lowering plasma homocysteine concentration with folic acid therapy reduce cardiovascular risk in patients with or at risk for atherosclerotic disease?
Does lowering plasma homocysteine concentration with folic acid therapy reduce cardiovascular risk in patients with or at risk for atherosclerotic disease?
This review concludes there is insufficient evidence to support widespread use of folic acid therapy to lower homocysteine for cardiovascular risk reduction.
Answers are grounded in this paper and cite their sources.
Contradictory evidence leaves homocysteine's role in atherosclerosis uncertain; does not support routine testing or treatment pending randomized trials.
BACKGROUND: An increased plasma level of homocysteine has been proposed as an independent risk factor for atherosclerosis; this review examines the evidence. METHODS: A Medline search was undertaken for English language articles on homocysteine and vascular disease. Further papers were identified by cross-referencing from the reference lists of relevant major articles. RESULTS: Although much interest has been generated about homocysteine and atherosclerotic disease, contradictory data exist regarding its role in disease progression. There is insufficient current evidence to regard increased homocysteine level as a causative factor in atherosclerotic disease. CONCLUSION: It is not known whether lowering plasma homocysteine concentration will reduce cardiovascular risk in the long term. Until such data become available, there is no evidence for the widespread use of folic acid therapy to reduce cardiovascular disease risk.
No takes yet. Share an insight, caveat, or question.
O’Grady et al. (2002) conducted a review in Atherosclerotic disease. Increased plasma homocysteine level was evaluated on Atherosclerotic disease progression. There is insufficient evidence to regard increased homocysteine levels as a causative factor in atherosclerotic disease or to support widespread folic acid therapy for cardiovascular risk reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: